 |
Life Technologies (India) Pvt Ltd. 306, Agarwal City Mall, opposite M2K Pitampura, Delhi-110034 (India) Tel # +91-11-4220-8000; 4220-8111; 4220-8222 Fax# +91-11-4220-8444, Mobile# +91-98105-21400 Email# customerservice@lifetechindia.com |
Cardiotoxicity
To comprehend the prolongation of the QT interval on the ECG, which precisely identifies the blockage occurring in the hERG channel, drug testing on cardiac action potential is conducted as part of the cardiac safety review. Providing automated electrophysiological tests is Life Technologies. Our proficiency in binding Q Patch HT automated patch clamp assays and manual patch clamp assays has not diminished. We have short turnaround times to check on your compounds that happen to have a cardiac liability and efficient, dependable, and cost-effective solutions that assist you predict cardiac risk earlier in your study.
In Vitro Assays Conducted by Life Technologies
- functional mitochondrial toxicity (Seahorse)
- hERG safety screening using Invitrogen’s Predictor™ hERG fluorescence polarization assay kit
- 3D microtissue-based cardiotoxicity assay using human iPSC – CM (cardiomyocytes) spheroid cultures
Panel Name
The Core Panel (3 Concentrations) of the Comprehensive in vitro Proarrhythmia Assay (CiPA)
Key Features
Three cardiac ion channel targets (hERG, hNav1.5 peak, and hCav1.2) are included in Tier 1 CiPA core panels. These targets are most frequently profiled beyond hERG for early cardiac risk assessment and mitigation. These panels provide a good starting point for predicting the risk of cardiac proarrhythmics. Each test is thoroughly validated by our knowledgeable electrophysiologists to enhance assay performance and reduce current rundown. Life Technologies provides trustworthy pharmacological test findings (with time-matched vehicle control and reference chemical data included in each report).
The Comprehensive in vitro Proarrhythmia Assay (CiPA) Core Panel (5 Concentrations)
Panel Name
The Comprehensive in vitro Proarrhythmia Assay (CiPA) Panel (3 Concentrations)
Key Features
The Tier 2 CiPA panels (Figure 2) suggested by the CiPA consortium comprise all seven cardiac ion channels as key regulators of the ventricular action potential. Our CiPA panels offer thorough mechanistic analysis to forecast proarrhythmic risk for the selection of important candidates to forward into first-in-human trials. Our CiPA assays offer Giga ohm seal data quality with established reference pharmacology that closely resembles manual patch clamp assays that are the industry standard. The most widely used automated patch clamp technology in the market, Q PatchTM HT, is being used by Life Technologies in procedures and instruments that comply with future regulatory criteria.
The Comprehensive in vitro Proarrhythmia Assay (CiPA) Panel (5 Concentrations)Human iPSC-derived cardiomyocytes FLIPR Penta assays
Assay Name
Human iPSC-derived cardiomyocytes FLIPR Penta assay (4 Concentrations)
Key Features
Robust reference pharmacology data on fully validated markers with strong translational values
Affordable, precise, and high throughput assay for cardiac liability assessment in intact, beating human ventricular-like stem cells, a good first phase screening method